Hemostemix (CVE:HEM) Trading Down 12.1% – Here’s Why

by · The Cerbat Gem

Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) fell 12.1% during mid-day trading on Thursday . The company traded as low as C$0.15 and last traded at C$0.15. 517,055 shares were traded during mid-day trading, a decline of 38% from the average session volume of 834,902 shares. The stock had previously closed at C$0.17.

Hemostemix Price Performance

The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The business’s 50-day simple moving average is C$0.22 and its 200-day simple moving average is C$0.13. The stock has a market cap of C$20.40 million, a PE ratio of -4.08 and a beta of 0.20.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Further Reading